Association of Nuclear Receptor Coactivators with Hypoxia-Inducible Factor-1α in the Serum of Patients with Chronic Kidney Disease

Table 1

NCOA1, NCOA2, NCOA3, HIF-1α, and VEFG levels between the CKD group and healthy control group.

Variables	Nondialysis group	Hemodialysis group	Peritoneal dialysis group	Chronic kidney disease group	Healthy control group
VEFG	727.45 (577.63, 945.40)	1047.50 (896.55, 1154.20)	1101.80 (886.95, 1146.20)	982.10 (786.03, 1140.25)	257.90 (191.53, 321.60)^abcd	69.605	0.000
HIF-1α	125.10 (116.15, 153.46)	121.33 (107.44, 127.25)	127.72 (107.00, 138.43)	124.40 (109.64, 132.60)	114.29 (73.42, 126.97)	8.483	0.075
NCOA1	1220.65 (930.84, 1377.90)	1139.46 (963.10, 1649.38)	1081.63 (974.25, 1188.29)	1120.84 (974.25, 1272.05)	1048.76 (804.52, 1153.97)	6.900	0.141
NCOA2	715.08 (595.14, 876.94)	802.82 (645.33, 1002.11)	832.60 (725.42, 937.41)	772.87 (655.58, 937.41)	697.39 (448.00, 829.62)	8.793	0.066
NCOA3	750.81 (613.14, 860.40)	761.21 (683.74, 860.40)	755.41 (685.46, 827.03)	758.89 (660.15, 855.13)	717.20 (518.15, 761.21)	6.095	0.192

Compared with the nondialysis group, ^a; compared with the hemodialysis group, ^b; compared with the peritoneal dialysis group, ^c; compared with the chronic kidney disease group, ^d.